Leadership & Pay ·
Tango Therapeutics, Inc. amended its prior Form 8-K to disclose the executed separation agreement with Executive Chair…
TNGXTango Therapeutics, Inc.
Tango Therapeutics, Inc. amended its prior Form 8-K to disclose the executed separation agreement with Executive Chair Barbara Weber, M.D., whose employment ended on August 3, 2026. The agreement provides severance pay through December 31, 2026, COBRA premium reimbursement until that date, a pro-rata portion of her 2026 annual incentive compensation payable by March 15, 2027, and full acceleration of outstanding option and restricted stock unit awards subject to Compensation Committee approval. Additionally, the post-termination exercise period for vested options is extended to August 3, 2027 or their original expiration date. This executive departure constitutes a material change in leadership for the clinical-stage biotechnology company focused on discovering precision cancer medicines via synthetic lethality.